Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase II drugs for Neuroendocrine Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lurbinectedin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lurbinectedin (Zepzelca) is a synthetic tetrahydropyrrolo [4, 3, 2-de] quinolin-8(1H)-one alkaloid analogue with potential anti-neoplastic activity. It is formulated as lyophilised powder for solution for intravenous route of administration. Zepzelca is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Lurbinectedin (PM-01183) is under development for the treatment of neuroendocrine gastroenteropancreatic tumors (GEP-NET), advanced or metastatic soft-tissue sarcoma, advanced or metastatic leiomyosarcoma, unresectable non-small cell lung cancer, malignant pleural mesothelioma, small cell lung cancer, HER2 positive metastatic breast cancer, metastatic colorectal cancer, gastric cancer, endometrial cancer, triple-negative breast cancer (TNBC), leukemias, neuroendocrine tumors, relapsed or primary refractory non-M3 acute myeloid leukemia, chronic myeloid leukemia, esophageal cancer, large cell neuroendocrine carcinoma of the lung, pancreatic adenocarcinoma, relapsed/refractory myelodysplastic syndrome, metastatic biliary tract carcinoma, head and neck carcinoma, relapsed or refractoryacute lymphocytic leukemia, germ cell cancer, soft tissue sarcoma, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), mesothelioma, glioblastoma, Ewing family of tumors, advanced solid tumors, metastatic pancreatic cancer, metastatic urothelial cell carcinoma, synovial sarcoma and neuroendocrine gastroenteropancreatic tumors. It is administered intravenously as a solution concentrate. It is a synthetic alkaloid which targets RNA polymerase II. It was also under development for the treatment of epithelial ovarian cancer peritoneal cancer, fallopian tube cancer, metastatic pancreatic cancer, hepatocellular carcinoma, bone cancer and bladder cancer.
Jazz Pharmaceuticals overview
Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Erwinaze (asparaginase erwinia chrysanthemi), Defitelio (defibrotide sodium), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
For a complete picture of Lurbinectedin’s drug-specific PTSR and LoA scores, buy the report here.